The largest database of trusted experimental protocols

Smad2 sirna

Manufactured by Santa Cruz Biotechnology
Sourced in United States

Smad2 siRNA is a laboratory reagent designed to suppress the expression of the Smad2 gene. Smad2 is a key intracellular signaling protein involved in the transforming growth factor-beta (TGF-β) signaling pathway. The siRNA targets Smad2 mRNA, leading to a reduction in Smad2 protein levels.

Automatically generated - may contain errors

2 protocols using smad2 sirna

1

Glioblastoma Cell Line Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols
The human glioblastoma cell lines U87 MG, U118 MG, U251 MG, A172, LN-229, and T98G were purchased from Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). The cells were cultured in DMEM supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, USA).
The antibodies against NAG-1, Bcl-2, Bax, caspase-3, caspase-8, caspase-9, cytochrome c, p-PI3K(p85 Tyr458)/PI3K(p85), p-Akt(Ser473)/Akt, p-ERK1/2(Thr202/Tyr204)/ERK1/2, p-Smad2(Ser465/467)/Smad2, p-Smad3(Ser423/425)/Smad3, and β-actin were purchased from Cell Signaling Technologies (Beverly, MA, USA). Wortmannin, LY294002, Smad2 siRNA, and Smad3 siRNA were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Ac-IETD-FMK and Ac-LEHD-FMK were purchased from KeyGEN Biotech Co., Ltd. (Nanjing, China). Enhanced chemiluminescence (ECL) detection system was purchased from Amersham Life Science (Arlington Heights, Illinois, USA). Human NAG-1 ELISA Kit was obtained from Huamei Biological Company (Wuhan, China). Mitochondrial membrane potential assay kit with JC-1 and protein A/G agarose beads were obtained from Beyotime Institute of Biotechnology (Shanghai, China). X-treme GENE siRNA transfection reagent was purchased from Roche Applied Science.
+ Open protocol
+ Expand
2

Investigating TGF-β and NF-κB Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following primary antibodies were used from Santa Cruz Biotechnology: pERK (T202/Y204), ERK1/2, TGF-β1–3, TGF-β1 siRNA, SMAD2 siRNA, siRNA, control siRNA, and β-actin. The following primary antibodies were used from Cell Signaling: NF-κBp65 (p65), PUMA, bcl-2, Mcl-1, Bcl-XL, PARP, Bax, Bak, Bid, Bim, and Caspase-3. NF-κBp65 siRNAs and hrTGF-β1 were from Applied Biosystems. MEK/ERK inhibitor U0126 was purchased from Cell Signaling Technology. Anti-Ki67 Ab was from Thermo Scientific. Inhibitors were tested for monotherapy and combination therapy: U0126:10 mM. Cells incubated with culture medium or culture medium with DMSO served as controls.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!